All In Biotech

Drug Trial Radar · NCT03359213

A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)

Phase II Study of JR-141 in Patients With Mucopolysaccharidosis II

Last checked: Nov 20, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jul 26, 2018

Primary completion

Oct 4, 2019

Study completion Oct 4, 2019

Sponsor

Lead sponsor
JCR Pharmaceuticals Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.

Conditions

  • Mucopolysaccharidosis II

Interventions

  • JR-141Drug

    IV infusion (lyophilized powder), 1.0 mg/kg/week

  • JR-141Drug

    IV infusion (lyophilized powder), 2.0 mg/kg/week

  • JR-141Drug

    IV infusion (lyophilized powder), 4.0 mg/kg/week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse EventsTime frame: 26 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Grupo de Pesquisa Clínica em Genética Médica - HCPA

    Porto Alegre, Brazil

  • Igeim - Unifesp

    São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.